Sainz-Amo, 211 patient vitamin D prophylaxis study: 33% lower severe cases [p=0.45] and 44% fewer cases [p=0.23] https://c19p.org/sainzamo
copied to clipboard
COVID-19 in Parkinson’s disease: what holds the key?
et al., Journal of Neurology, doi:10.1007/s00415-020-10272-0
Case control study with 39 COVID+ and 172 COVID- Parkinson's disease patients in Spain, showing positive and severe cases being less likely to use vitamin D supplementation compared to negative or mild/negative cases respectively. These differences were not statistically significant.
|
risk of severe case, 32.7% lower, OR 0.67, p = 0.45, treatment 5 of 29 (17.2%) cases,
43 of 182 (23.6%) controls, NNT 23, case control OR.
|
|
risk of case, 43.7% lower, OR 0.56, p = 0.23, treatment 6 of 39 (15.4%) cases,
42 of 172 (24.4%) controls, NNT 13, case control OR.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Sainz-Amo et al., 10/24/2020, retrospective, Spain, Europe, peer-reviewed, mean age 74.5, 13 authors, dosage not specified.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.